Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Promis Neurosciences Inc    PMN   CA74346M1095

PROMIS NEUROSCIENCES INC

(PMN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
03/13/2019 03/14/2019 03/15/2019 03/18/2019 03/19/2019 Date
0.375(c) 0.38(c) 0.37(c) 0.37(c) 0.36(c) Last
374 986 144 695 446 336 397 792 156 900 Volume
-2.60% +1.33% -2.63% 0.00% -2.70% Change
More quotes
Financials (CAD)
Sales 2019 10,0 M
EBIT 2019 -1,80 M
Net income 2019 -1,80 M
Debt 2019 -
Yield 2019 -
Sales 2020 39,0 M
EBIT 2020 26,6 M
Net income 2020 23,4 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 3,43
Capi. / Sales2019 9,23x
Capi. / Sales2020 2,37x
Capitalization 92,3 M
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease... 
More about the company
Latest news on PROMIS NEUROSCIENCES INC
03/19PROMIS NEUROSCIENCES : to Present Data for Potential Best-in-Class Antibody Cand..
PR
03/19PROMIS NEUROSCIENCES : to Present Data for Potential Best-in-Class Antibody Cand..
AQ
03/19PROMIS NEUROSCIENCES : to Present Data for Potential Best-in-Class Antibody Cand..
AQ
03/18PROMIS NEUROSCIENCES : Announces Fiscal Year 2018 Annual Results
AQ
03/16PROMIS NEUROSCIENCES : Announces Fiscal Year 2018 Annual Results
AQ
03/16PROMIS NEUROSCIENCES : Announces Fiscal Year 2018 Annual Results
AQ
03/15ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
GL
02/21PROMIS NEUROSCIENCES : Adds Pharmaceutical Leader Timothy Rothwell to Board of A..
PR
02/13PROMIS NEUROSCIENCES : Identifies Several Antibody Drug Candidates Showing Best-..
AQ
02/12PARKINSON'S DISEASE : ProMIS Neurosciences Identifies Several Antibody Drug Cand..
AQ
More news
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart PROMIS NEUROSCIENCES INC
Duration : Period :
Promis Neurosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 0,75  CAD
Spread / Average Target 108%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES INC37.04%69
GILEAD SCIENCES4.70%83 533
VERTEX PHARMACEUTICALS13.15%46 468
REGENERON PHARMACEUTICALS8.97%43 697
GENMAB4.54%10 456
SAREPTA THERAPEUTICS INC15.89%9 318